Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Titre officiel

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Sommaire:

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Description de l'essai

Primary Outcome:

  • Progression-free survival (PFS)
  • Overall Survival (OS)
Secondary Outcome:
  • Overall Survival (OS)
  • Objective Response Rate (ORR)
  • Progression-free survival PFS
  • Progression-free survival at 18 months (PFS18)
  • Progression-free survival at 24 months (PFS24)
  • Time to death or distant metastasis (TTDM)
  • Proportion of patients alive at 24 months (OS24)
  • Proportion of patients alive at and 36 months (OS36)
  • Time from randomization to second progression (PFS2)
  • To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-C30 v3
  • To assess the PK of durvalumab and tremelimumab in blood (peak trough concentration)
  • Presence of anti-drug antibodies (ADA) for durvalumab and tremelimumab (confirmatory results: positive or negative)
  • To assess a relationship between a tumour mutational burden (TMB) measured as biomarker presence in tumour and/or blood and Progression-free survival (PFS) with durvalumab and durvalumab and tremelimumab combination therapy
  • To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-LC13
  • To assess a relationship between a tumour mutational burden (TMB) measured as biomarker presence in tumour and/or blood and Objective Response Rate (ORR) with durvalumab and durvalumab and tremelimumab combination therapy
  • To assess a relationship between a tumour mutational burden (TMB) measured as biomarker presence in tumour and/or blood and Overall Survival (OS) with durvalumab and durvalumab and tremelimumab combination therapy

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer